Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1

Thrombosis and Haemostasis

Volumn 104, Issue 3, 2010, Pages 464-470

  Lau, Wei Ling ^a   Festing, Maria H ^b   Giachelli, Cecilia M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

Author keywords

Kidney disease; Phosphate; Pit 1; Vascular calcification

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA SMOOTH MUSCLE ACTIN; CALCITRIOL; CARRIER PROTEIN; COLECALCIFEROL; COLLAGEN; COLLAGEN TYPE 1; ELASTIN; FIBROBLAST GROWTH FACTOR 23; FOSCARNET; GELATINASE B; HYDROXYAPATITE; OSTEOCALCIN; OSTEOPONTIN; OXYGENASE; PARATHYROID HORMONE; PHOSPHATASE; PHOSPHATE; PHOSPHONIC ACID DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PYROPHOSPHATE; S (1,2 DICHLOROVINYL)CYSTEINE; SECRETED FRIZZLED RELATED PROTEIN 1; SMALL INTERFERING RNA; SODIUM DEPENDENT PHOSPHATE COTRANSPORTER PIT1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

BACTERIAL GENE; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; BONE REMODELING; CARDIOVASCULAR DISEASE; CELL FATE; CELL FUNCTION; CELL PROLIFERATION; CHEMICAL BOND; CHONDROGENESIS; CHRONIC KIDNEY DISEASE; DEPHOSPHORYLATION; DRIVE; EMBRYO DEVELOPMENT; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISEASE; NONHUMAN; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; POPULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; UREMIA; VASCULAR SMOOTH MUSCLE;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD VESSELS; CALCINOSIS; CARDIOVASCULAR DISEASES; GENE KNOCKDOWN TECHNIQUES; HOMEOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; PHOSPHATES; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE III;

EID: 77956633892     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-12-0814     Document Type: Review

References (81)

1. London G, Marchais S, Guérin A, et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525-531. (Pubitemid 41531842)
2. Collins A, Li S, Gilbertson D, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003; 87: S24-31.
3. USRDS. United States Renal Data System Annual Data Report; 2009 http://www.usrds.org/adr.htm accessed on Oct 14, 2009.
4. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401. (Pubitemid 26075849)
5. Ibels L, Alfrey A, Huffer W, et al. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66: 790-796.
6. Hruska K, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-157.
7. Demer L, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117: 2938-2948.
8. Shroff R, McNair R, Figg N, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008; 118: 1748-1757.
9. Blacher J, Safar M, Guerin A, et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63: 1852-1860. (Pubitemid 36513333)
10. Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
11. Ahmed S, O'Neill K, Hood A, et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001; 37: 1267-1276.
12. Goldman L, Ausiello D. Cecil Medicine. 23rd ed. Saunders Elsevier; 2007.
13. Villa-Bellosta R, Ravera S, Sorribas V, et al. The Na+-Pi cotransporter PiT-2 (SLC20A2) is expressed in the apical membrane of rat renal proximal tubules and regulated by dietary Pi. Am J Physiol Renal Physiol 2009; 296: F691-699.
14. Reichel H, Deibert B, Schmidt-Gayk H, et al. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-169.
15. Hattenhauer O, Traebert M, Murer H, et al. Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake. Am J Physiol 1999; 277: G756-762.
16. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
17. El-Abbadi M, Pai A, Leaf E, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 75: 1297-1307.
18. Block G, Hulbert-Shearon T, Levin N, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617. (Pubitemid 28158000)
19. Young E, Albert J, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
20. Dhingra R, Sullivan L, Fox C, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
21. Kestenbaum B, Sampson J, Rudser K, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
22. Chertow G, Burke S, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252. (Pubitemid 34754068)
23. Block G, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
24. Suki W, Zabaneh R, Cangiano J, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
25. St Peter W, Liu J, Weinhandl E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51: 445-454.
26. Jono S, McKee M, Murry C, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-17.
27. Cozzolino M, Staniforth M, Liapis H, et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003; 64: 1653-1661.
28. Block G, Spiegel D, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
29. Steitz S, Speer M, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
30. Wada T, McKee M, Steitz S, et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84: 166-178. (Pubitemid 29070112)
31. Graciolli F, Neves K, dos Reis L, et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant 2009; 24: 1416-1421.
32. Speer M, Yang H, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009; 104: 733-741.
33. Román-García P, Carrillo-López N, Fernández-Martín J, et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121-128.
34. Reynolds J, Joannides A, Skepper J, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857-2867.
35. Shroff R, McNair R, Skepper J, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010; 21: 103-112.
36. Son B, Kozaki K, Iijima K, et al. Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur J Pharmacol 2007; 556: 1-8.
37. Son B, Kozaki K, Iijima K, et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 2006; 98: 1024-1031.
38. Zhang S, Fantozzi I, Tigno D, et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 285: L740-754.
39. Murshed M, Harmey D, Millán J, et al. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19: 1093-1104. (Pubitemid 40632454)
40. Lomashvili K, Cobbs S, Hennigar R, et al. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 2004; 15: 1392-1401.
41. Lomashvili K, Garg P, Narisawa S, et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008; 73: 1024-1030.
42. Rucker R. Calcium binding to elastin. Adv Exp Med Biol 1974; 48: 185-209.
43. Bouvet C, Moreau S, Blanchette J, et al. Sequential activation of matrix metalloproteinase 9 and transforming growth factor beta in arterial elastocalcinosis. Arterioscler Thromb Vasc Biol 2008; 28: 856-862. (Pubitemid 351544099)
44. Hosaka N, Mizobuchi M, Ogata H, et al. Elastin Degradation Accelerates Phosphate-Induced Mineralization of Vascular Smooth Muscle Cells. Calcif Tissue Int 2009; 85: 523-529.
45. Simionescu A, Philips K, Vyavahare N. Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells. Biochem Biophys Res Commun 2005; 334: 524-532.
46. Heldin C, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
47. Lee K, Kim H, Li Q, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000; 20: 8783-8792.
48. Basalyga D, Simionescu D, Xiong W, et al. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110: 3480-3487. (Pubitemid 39602227)
49. Chung A, Yang H, Sigrist M, et al. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res 2009; 84: 494-504.
50. Takeda E, Taketani Y, Morita K, et al. Sodium-dependent phosphate co-transporters. Int J Biochem Cell Biol 1999; 31: 377-381.
51. Werner A, Dehmelt L, Nalbant P. Na+-dependent phosphate cotransporters: the NaPi protein families. J Exp Biol 1998; 201: 3135-3142.
52. Villa-Bellosta R, Bogaert Y, Levi M, et al. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol 2007; 27: 1030-1036. (Pubitemid 46641988)
53. Li X, Yang H, Giachelli C. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912. (Pubitemid 43755243)
54. Villa-Bellosta R, Sorribas V. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium-phosphate deposition. Arterioscler Thromb Vasc Biol 2009; 29: 761-766.
55. Ravera S, Virkki L, Murer H, et al. Deciphering PiT transport kinetics and substrate specificity using electrophysiology and flux measurements. Am J Physiol Cell Physiol 2007; 293: C606-620.
56. Li X, Yang H, Giachelli C. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis 2008; 199: 271-277.
57. Suzuki A, Ghayor C, Guicheux J, et al. Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells. J Bone Miner Res 2006; 21: 674-683.
58. Yang H, Curinga G, Giachelli C. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299.
59. Villa-Bellosta R, Levi M, Sorribas V. Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. Pflugers Arch 2009; 458: 1151-1161.
60. Kakita A, Suzuki A, Nishiwaki K, et al. Stimulation of Na-dependent phosphate transport by platelet-derived growth factor in rat aortic smooth muscle cells. Atherosclerosis 2004; 174: 17-24.
61. Gallea S, Lallemand F, Atfi A, et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001; 28: 491-498.
62. Wang Z, Wang D, Hockemeyer D, et al. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 2004; 428: 185-189. (Pubitemid 38374315)
63. Xiao G, Jiang D, Thomas P, et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 2000; 275: 4453-4459.
64. Heldin C, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283-1316. (Pubitemid 29473317)
65. Johann S, Gibbons J, O'Hara B. GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J Virol 1992; 66: 1635-1640.
66. Miller D, Edwards R, Miller A. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 1994; 91: 78-82.
67. Kavanaugh M, Miller D, Zhang W, et al. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA 1994; 91: 7071-7075.
68. Olah Z, Lehel C, Anderson W, et al. The cellular receptor for gibbon ape leukemia virus is a novel high affinity sodium-dependent phosphate transporter. J Biol Chem 1994; 269: 25426-25431. (Pubitemid 24336228)
69. Collins J, Bai L, Ghishan F. The SLC20 family of proteins: dual functions as sodium-phosphate cotransporters and viral receptors. Pflugers Arch 2004; 447: 647-652.
70. Palmer G, Zhao J, Bonjour J, et al. In vivo expression of transcripts encoding the Glvr-1 phosphate transporter/retrovirus receptor during bone development. Bone 1999; 24: 1-7.
71. Beck L, Leroy C, Salaun C, et al. Identification of a novel function of PiT1 critical for cell proliferation and independent from its phosphate transport activity. J Biol Chem 2009; 284: 31363-31374.
72. Segawa H, Onitsuka A, Furutani J, et al. Npt2a and Npt2c in mice play distinct and synergistic roles in inorganic phosphate metabolism and skeletal development. Am J Physiol Renal Physiol 2009; 297: F671-678.
73. Shibasaki Y, Etoh N, Hayasaka M, et al. Targeted deletion of the tybe IIb Na+-dependent Pi-co-transporter, NaPi-IIb, results in early embryonic lethality. Biochemical and Biophysical Research Communications 2009; 381: 482-486.
74. Festing M, Speer M, Yang H, et al. Generation of mouse conditional and null alleles of the type III sodium-dependent phosphate cotransporter PiT-1. Genesis 2009; 47: 858-863.
75. Beck L, Leroy C, Beck-Cormier S, et al. The phosphate transporter PiT1 (Slc20a1) revealed as a new essential gene for mouse liver development. PLoS One 2010; 5: e9148.
76. Walsh M, Manns B, Klarenbach S, et al. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. Hemodial Int 2010; 14: 174-181.
77. Davenport A, Gardner C, Delaney M. The effect of dialysis modality on phosphate control : haemodialysis compared to haemodiafiltration. The Pan Thames Renal Audit. Nephrol Dial Transplant 2010; 25: 897-901.
78. Kuhlmann M. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif 2010; 29: 137-144.
79. Ahlenstiel T, Pape L, Ehrich J, et al. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Nephrol Dial Transplant 2010; epub ahead of print.
80. Kalantar-Zadeh K, Gutekunst L, Mehrotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 519-530.
81. Navaneethan S, Palmer S, Craig J, et al. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009; 54: 619-637.